Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Larisa V. Gubareva"'
Autor:
Krista Kniss, Juan A. De La Cruz, Anton Chesnokov, Larisa V. Gubareva, Angiezel Merced-Morales, Jennifer Laplante, Kirsten St. George, David E. Wentworth, Rebecca Kondor, Teena Mohan, Ha T. Nguyen, Vasiliy P. Mishin, Patricia A. Blevins
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 7, Pp 1953-1957 (2021)
Emerging Infectious Diseases
Emerging Infectious Diseases
Four cases of oseltamivir-resistant influenza A(H1N1)pdm09 virus infection were detected among inhabitants of a border detention center in Texas, USA. Hemagglutinin of these viruses belongs to 6B.1A5A-156K subclade, which may enable viral escape from
Autor:
Vasiliy P, Mishin, Mira C, Patel, Anton, Chesnokov, Juan, De La Cruz, Ha T, Nguyen, Lori, Lollis, Erin, Hodges, Yunho, Jang, John, Barnes, Timothy, Uyeki, Charles T, Davis, David E, Wentworth, Larisa V, Gubareva
Publikováno v:
Emerging Infectious Diseases
Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2–98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses
Autor:
Krista Kniss, Lynnette Brammer, Xiyan Xu, Melissa A Rolfes, Larisa V. Gubareva, Alicia P Budd, Lenee Blanton, Sankan Nyanseor, James Stevens, John Barnes, Charisse N Cummings, Alissa O’Halloran, Alicia M. Fry, Anwar Isa Abd Elal, Erin Burns, Noreen Alabi, Matthew Biggerstaff, Wendy Sessions, Rebecca Kondor, David E. Wentworth, Shikha Garg, Daniel B. Jernigan, Vivien G. Dugan
Publikováno v:
Morbidity and Mortality Weekly Report
Influenza activity* in the United States during the 2018-19 season (September 30, 2018-May 18, 2019) was of moderate severity (1). Nationally, influenza-like illness (ILI)† activity began increasing in November, peaked during mid-February, and retu
Autor:
Jackie Katz, Rebecca Garten, Anton Chesnokov, Vasiliy P. Mishin, Heather Reid, John Barnes, Angela P Campbell, Mira C. Patel, Ha T. Nguyen, Sarah Spencer, Larisa V. Gubareva, Juan A. De La Cruz, Mallory Sinner, David E. Wentworth, Alicia M. Fry
Publikováno v:
Eurosurveillance
The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one
Autor:
Margaret, Okomo-Adhiambo, Alicia M, Fry, Su, Su, Ha T, Nguyen, Anwar Abd, Elal, Elizabeth, Negron, Julie, Hand, Rebecca J, Garten, John, Barnes, Xu, Xiyan, Julie M, Villanueva, Larisa V, Gubareva, Reginald, McClinton
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 1, Pp 136-141 (2015)
Emerging Infectious Diseases
Emerging Infectious Diseases
We report characteristics of oseltamivir-resistant influenza A(H1N1)pdm09 viruses and patients infected with these viruses in the United States. During 2013–14, fifty-nine (1.2%) of 4,968 analyzed US influenza A(H1N1)pdm09 viruses had the H275Y ose
Autor:
Larisa V. Gubareva, Katrina Sleeman, Amanda Balish, Vasiliy P. Mishin, Rebecca Garten, Alicia M. Fry, Julie Villanueva, Zhu Guo, James Stevens
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:2045-2051
Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not
Autor:
Daniel B. Jernigan, Lynnette Brammer, Mei Shang, Lisa A. Grohskopf, Natalie Kramer, Stacy L. Davlin, Anwar Isa Abd Elal, Brendan Flannery, Erin Burns, David E. Wentworth, Shikha Garg, Stephen Barnes, Sonja J. Olsen, Larisa V. Gubareva, Noreen Alabi, Desiree Mustaquim, Alicia P Budd, Joseph S. Bresee, Xiyan Xu, Rebecca Garten, John R. Barnes, Charisse N Cummings, Alicia M. Fry, Lenee Blanton, Jacqueline M. Katz, Wendy Sessions, Krista Kniss
Publikováno v:
MMWR. Morbidity and mortality weekly report. 65(50-51)
This report summarizes U.S. influenza activity* during October 2-December 17, 2016.† Influenza activity in the United States remained low in October and has been slowly increasing since November. Influenza A viruses were identified most frequently,
Autor:
Aaron D, Storms, Larisa V, Gubareva, Su, Su, John T, Wheeling, Margaret, Okomo-Adhiambo, Chao-Yang, Pan, Erik, Reisdorf, Kirsten, St George, Robert, Myers, Jason T, Wotton, Sara, Robinson, Brandon, Leader, Martha, Thompson, Marjorie, Shannon, Alexander, Klimov, Alicia M, Fry, Ha, Nguyen
Publikováno v:
Emerging Infectious Diseases, Vol 18, Iss 2, Pp 308-311 (2012)
Emerging Infectious Diseases
Emerging Infectious Diseases
During October 2010–July 2011, 1.0% of pandemic (H1N1) 2009 viruses in the United States were oseltamivir resistant, compared with 0.5% during the 2009–10 influenza season. Of resistant viruses from 2010–11 and 2009–10, 26% and 89%, respectiv
Autor:
Larisa V. Gubareva, Katrina Sleeman, Zack Moore, Alicia M. Fry, Susan Kilpatrick, Shikha Garg, Tiffany G. Sheu
Publikováno v:
Emerging Infectious Diseases, Vol 17, Iss 11, Pp 2043-2046 (2011)
Emerging Infectious Diseases
Emerging Infectious Diseases
Oseltamivir is 1 of 2 antiviral medications available for the treatment of influenza B virus infections. We describe and characterize a cluster of influenza B viruses circulating in North Carolina with a mutation in the neuraminidase active site that
Autor:
Margaret Okomo-Adhiambo, Larisa V. Gubareva, Katrina Sleeman, Anwar Isa Abd Elal, Ha T. Nguyen, Alicia M. Fry
Publikováno v:
Influenza and Other Respiratory Viruses
Background Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpret